ImaginAb, Glaxo collaborate on therapeutic antibody
ImaginAb and the GlaxoSmithKline’s (GSK) Clinical Imaging Centre have concluded two research collaboration agreements around a clinical therapeutic antibody asset currently under development by GlaxoSmithKline in the field of oncology.
Paul Matthews, MD, vice president for translational research and head of the GSK’s Clinical Imaging Centre based at Hammersmith Hospital in London, said, "As we expand and develop our pipeline, technologies such as ImaginAb's recombinant antibody fragment engineering technology may help us to look at targeted molecular therapeutics in new ways."
ImaginAb is an early-stage biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy, located in Inglewood, Calif.
Paul Matthews, MD, vice president for translational research and head of the GSK’s Clinical Imaging Centre based at Hammersmith Hospital in London, said, "As we expand and develop our pipeline, technologies such as ImaginAb's recombinant antibody fragment engineering technology may help us to look at targeted molecular therapeutics in new ways."
ImaginAb is an early-stage biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy, located in Inglewood, Calif.